BioSante Pharmaceuticals, Inc. To Present Validation Data Required for Development of LibiGel(R) (transdermal testosterone gel) in the Treatment of Female Sexual Dysfunction

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (Amex:BPA) announced today that it has successfully completed validation studies required as part of the clinical development program of LibiGel for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD). The data will be presented today at the annual meeting of the North American Menopause Society in Dallas, Texas.